ASC Therapeutics Announces Partnership With University of Massachusetts Medical School to Co-Develop Novel Gene Therapy for Maple Syrup Urine Disease
MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies, today announced a partnership with the University of Massachusetts Medical School (UMMS) to co-develop a gene therapy for Maple Syrup Urine Disease (MSUD). “We look forward to working with the UMMS team led … Read more